Fundraising Fox

Envisagenics

New York, US · Founded 2014 · Delaware corporation · 4 known investors

envisagenics.com ↗

Envisagenics uses AI-driven analysis of RNA splicing to discover novel drug targets for immuno-oncology and neurodegenerative diseases. The company combines RNA biology expertise with machine learning to advance precision medicines.

AI & Machine LearningBiotechMedical Devicesin /envisagenics

Founders & leadership

MPMaria Pineda, PhD
Maria Pineda, PhDCEO & Co-founder
MAMartin Akerman, PhD
Martin Akerman, PhDCEO & Co-founder
MA
Martin AkermanExecutive Officer, Director, Promoter
ML
Maria Luisa PinedaExecutive Officer, Director, Promoter

Investors · 4

Dynamk CapitalNew York
Madrona Venture GroupSeattle · $2M – $10M
Dolby Family Venturesreported · 2 sourcesSan Francisco
Third Kind Venture CapitalreportedNew York · $50K – $5M

Reported raises · per SEC filings

Form D private placements
▶$19.2MraisedOct 2021 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • ALAN S. ROEMERDirector
  • BRADLEY HARRISExecutive Officer
  • MARTIN AKERMANExecutive Officer, Director
  • GRANT VERSTANDINGDirector
  • MARIA LUISA PINEDAExecutive Officer, Director
Offering amount
$19.2M
Amount sold
$19.2M
Minimum investment
$1
First sale
Sep 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedOct 2017 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin AkermanExecutive Officer, Director, Promoter
  • Maria Luisa PinedaExecutive Officer, Director, Promoter
Offering amount
$2.5M
Amount sold
$2.5M
First sale
Mar 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news